Expert Reviews in Molecular Medicine

cambridge.org/erm

Review

*These authors contributed equally.

Cite this article: Yanakiev M, Soper O, Berg DA, Kang E (2023). Modelling Alzheimer's disease using human brain organoids: current progress and challenges. *Expert Reviews in Molecular Medicine* **25**, e3, 1–12. https://doi.org/10.1017/erm.2022.40

Received: 16 June 2022
Revised: 23 November 2022
Accepted: 5 December 2022

Key words:
3D-culture; Alzheimer's disease; amyloid-β; human brain organoids; human iPSCs; neurodegenerative disorder; neuroinflammation; tau

Author for correspondence:
Eunchai Kang,
E-mail: eunchai.kang@abdn.ac.uk

© The Author(s), 2022. Published by Cambridge University Press

CAMBRIDGE UNIVERSITY PRESS

Modelling Alzheimer's disease using human brain organoids: current progress and challenges

Mario Yanakiev*, Olivia Soper*, Daniel A. Berg and Eunchai Kang

Institute of Medical Sciences, School of Medicine, Medical Sciences and Nutrition, University of Aberdeen, Aberdeen AB25 2ZD, UK

Abstract

Alzheimer's disease (AD) is a progressive neurodegenerative disorder characterised by gradual memory loss and declining cognitive and executive functions. AD is the most common cause of dementia, affecting more than 50 million people worldwide, and is a major health concern in society. Despite decades of research, the cause of AD is not well understood and there is no effective curative treatment so far. Therefore, there is an urgent need to increase understanding of AD pathophysiology in the hope of developing a much-needed cure. Dissecting the cellular and molecular mechanisms of AD pathogenesis has been challenging as the most commonly used model systems such as transgenic animals and two-dimensional neuronal culture do not fully recapitulate the pathological hallmarks of AD. The recent advent of three-dimensional human brain organoids confers unique opportunities to study AD in a humanised model system by encapsulating many aspects of AD pathology. In the present review, we summarise the studies of AD using human brain organoids that recapitulate the major pathological components of AD including amyloid-β and tau aggregation, neuroinflammation, mitochondrial dysfunction, oxidative stress and synaptic and circuitry dysregulation. Additionally, the current challenges and future directions of the brain organoids modelling system are discussed.

Introduction

Alzheimer's disease (AD) is a progressive neurodegenerative disorder, characterised primarily by gradual memory loss, cognitive impairment and executive dysfunction. It is the leading cause of dementia, which currently affects over 50 million people worldwide and is projected to rise to 150 million by 2050 (Ref. 1). The lack of disease-modifying or curative treatments for AD represents a lasting impact on the health and lives of patients, as well as on the healthcare and social service sectors, with global annual costs surpassing $1 trillion (Ref. 2). This number is estimated to be more than doubled by 2050, putting the economic burden of dementia care higher than that of both cancer and heart disease (Ref. 3). Together these figures suggest a pressing need for improved AD and dementia diagnosis, treatment and prevention, along with a better understanding of the causes and mechanisms of the disease in the hopes of discovering a much-needed cure.

The two core pathological hallmarks of end-stage AD include amyloid plaques, containing aggregates of misfolded amyloid-β (Aβ) protein, and neurofibrillary tangles (NFTs) of hyperphosphorylated tau protein. Amyloid plaques are generated by the assembly of monomeric Aβ into oligomers and subsequently into fibrillar species, which aggregate in the extracellular space (Refs 4, 5, 6), whereas NFTs are formed in neuronal cell bodies and axons. Recent evidence suggests that amyloid plaques and fibrils alone are insufficient to induce an AD phenotype (Refs 7, 8) but play a role in the deposition and spread of tau tangles, which are more closely linked to neurotoxicity and symptom progression (Ref. 9). However, these pathological changes transpire numerous years prior to the onset of cognitive impairment, by which point considerable neuronal loss has occurred in the hippocampal area and has begun to spread into the neocortex (Ref. 10). Although NFTs could underlie progressive neuronal death, the presence and accumulation of Aβ species have nevertheless been associated with other prominent aspects of AD pathology. Soluble Aβ oligomers have been implicated to cause mitochondrial and endoplasmic reticulum dysfunction, leading to overproduction of reactive oxygen species (ROS) and subsequent oxidative stress and neuronal damage (Ref. 11). Additionally, Aβ oligomers and fibrils can impair functional synaptic connections and activity, which is believed to underlie the cognitive decline, particularly in the prodromal and early stages of AD (Ref. 12).

Despite the significant advances made in understanding the pathological processes in AD, scientists have yet to discover what causes the majority of AD cases. Currently, there are several known genetic mutations that cause early-onset familial AD (fAD), a type of AD which is inherited in an autosomal dominant manner. fAD mutations are found in the *APP* gene, encoding the amyloid precursor protein from which Aβ is derived, as well as the *PSEN1* and *PSEN2* genes. These genes encode the presenilin 1 and 2 subunits of the γ-secretase enzyme which catalyses the cleavage of APP (Refs 13, 14). However, fAD only represents

CrossMark

~1% of total AD cases, with the rest being defined as late-onset sporadic AD (sAD) (Ref. 4). The causes of sAD are still unknown, but several factors have been shown to modify the risk of developing sAD, such as environmental, lifestyle, ethnic, socioeconomic and genetic factors (Refs 15, 16). In particular, identifying the genetic risk factors of sAD has received much attention within AD research, aiming to uncover novel pathological pathways and mechanisms of the disease. Most notably, a variant of the *APOE* gene – *APOE4* – has been identified as the biggest known genetic risk factor for AD (Ref. 17). The rise of next-generation sequencing technology has allowed for the identification of numerous other risk genes, some of which (e.g. *TREM2*, *CD33*, *CR1*, *MS4A*, *ABCA7*) have shown enrichment in microglia, the immune cells of the nervous system (Refs 18, 19, 20, 21) and in astrocytes (APOE, CLU) (Refs 17, 22). This observation has prompted increasing interest in the potential role of microglia within the pathological landscape of AD because of their role in neuroinflammation. Neuroinflammation is noted as the third core neuropathological hallmark of AD, besides amyloid plaques and NFTs, and is typically defined as inflammation within the spinal cord or brain mediated by the production of chemokines (CXCL1, CCL5, CCL2), cytokines (interleukin (IL)-1β, IL-18, tumour necrosis factor alpha (TNFα)) and ROS (Ref. 23). Many of these mediators are produced by microglia which account for ~10% of the adult brain cell population (Refs 24, 25). The increase in the production of pro-inflammatory mediators results in synaptic dysfunction, neuronal death and inhibition of neurogenesis (Ref. 26). Mounting evidence in recent years has shown that microglia exist in an aberrantly active state in AD, maintaining a chronic inflammatory phenotype in response to the pathological stimuli of Aβ and tau species (Ref. 26). This activation of microglia has been implicated in further increasing protein aggregation and deposition and exacerbating neuronal damage and degeneration. It is believed to be a key mediator of cognitive deterioration in the mid- to late-stages of AD (Refs 27, 28). Similarly, astrocytes can respond to the neurotoxic stimuli present in AD and propagate inflammation and tissue damage. Reactive astrogliosis has been shown to occur in AD both as a result of microglia-secreted pro-inflammatory factors, such as IL-1, TNFα and C1q (Ref. 29) and direct binding of Aβ species to astrocytic receptors. Moreover, sustained activation of astrocytes can lead to abnormal activation of the nuclear factor-κB pathway and subsequent secretion of pro-inflammatory molecules and ROS, and dysregulation of glucose metabolism, which can accelerate Aβ production and neuronal degeneration (Ref. 30). Furthermore, levels of inflammatory mediators, such as cytokines, chemokines and complement factors have been found to be elevated long before the clinical symptoms of AD, thus showing the importance of inflammation in the multifactorial pathogenesis of the disease (Ref. 31). However, mechanisms by which neuroinflammation impacts the development and/or progression of AD have not yet been understood. Thus, elucidating the genetic and molecular triggers of neuroinflammation, and its role in AD pathology, is another challenge which is vital to understand how AD arises and progresses.

Model systems for Alzheimer's disease

The vast complexity of AD pathology has necessitated the development and refinement of various preclinical disease models, including, but not limited to, transgenic animals, two-dimensional (2D) cell cultures, three-dimensional (3D) cell cultures and 3D brain organoids. These models aim to mimic the human brain environment as closely as possible and are critical to understanding AD pathology and assessing novel therapeutics (Ref. 32).

Transgenic animals

Transgenic animals (especially murine) are one of the most widely used and well-characterised model systems to study AD and have greatly advanced our knowledge of the genetic and molecular mechanisms of AD pathophysiology, as they provide the advantage of an in vivo environment with complex cell interactions, similar to the human brain. However, transgenic animals display inherent limitations which make it impossible for them to fully recapitulate all the hallmarks of AD or place them in a biologically relevant context. For example, transgenic mice, the most commonly used AD animal model, exhibit overt amyloid plaque deposition in the brain, through the insertion of human *APP* and/or *PSEN1* genes, carrying known fAD-causing mutations, into the host genome (Refs 8, 33). As such, they are engineered to overexpress the human AD transgenes at non-physiological levels (Ref. 34). This typically results in accelerated pathology with overt Aβ deposition and cognitive decline at an early age (Ref. 7), eliminating the age-dependent factor of AD pathogenesis. Additionally, human *APP/PSEN1* transgenics fail to exhibit tau NFT pathology (Ref. 35), which can be observed only through the addition of a mutated human tau *MAPT* gene (Ref. 36); however, mutations in *MAPT* have not been linked to AD in humans, diminishing the fidelity of this model in recapitulating AD pathogenesis (Ref. 37). Thus, it is important to recognise that these animal models do not have AD, they recapitulate certain neuropathological aspects of AD, most commonly in a non-physiological manner (Ref. 32). Transgenic animals also typically have a limited reproducibility of an sAD phenotype, because of the various genetic and environmental risk factors underlying its pathogenesis.

2D human induced pluripotent stem cell (iPSC)-derived neuronal culture models

With the rise of stem cell technology, new in vitro humanised models have been generated in attempts to circumvent these limitations seen with transgenic animals (Refs 38, 39, 40). 2D iPSC-derived neuronal cell cultures have been a valuable tool in recapitulating some of the key features of AD pathology, such as elevated Aβ levels and tau hyperphosphorylation (Ref. 41). Importantly, the breakthrough of iPSC technology has enabled the study of patient-specific disease signatures against a genuine genetic background. Thus, 2D iPSC-derived neuronal cultures have provided a simplified, yet biologically relevant medium to examine disease-specific cellular and molecular mechanisms, while also being a relatively inexpensive, well-established model system (Ref. 42). However, 2D cultures have inherent limitations, which preclude them from faithfully recapitulating the full extent of AD pathology. For example, 2D cultures do not exhibit Aβ plaques, as seen in the human brain. This is because of the organisation of the cells in a monolayer, resulting in increased diffusion of the Aβ species into the cell media, which are then lost upon replacement of the media (Ref. 43). Additionally, because of spatial restrictions, 2D cultures lack cytoarchitecture, which limits the degree of cell-to-cell interactions which are fundamental when considering the spread and progression of AD pathology. Although 2D models are sufficient to demonstrate elements of the pathophysiological mechanisms of AD, they cannot reproduce all of the disease hallmarks, most commonly the production of NFTs and the presence of glial cells which play important roles in the pathogenesis of AD (Refs 30, 44).

Human brain organoids

Because of the inherent limitations of the previously described model systems, 3D modelling technologies are being explored to

https://doi.org/10.1017/erm.2022.40 Published online by Cambridge University Press

improve our understanding of AD. In particular, human brain organoids have increasingly been used in recent years to model and study various neurodegenerative diseases, including AD. Brain organoids are a 3D self-assembling system, exhibiting functional and structural features of the foetal human brain. They are generated from human stem cell-derived embryoid bodies cultivated under 3D growth conditions (Refs 45, 46). Under such conditions, these stem cell aggregates possess the capacity to form organised structures, composed of neuronal progenitor and glial cell types and thus recapitulate the cellular and structural composition, and developmental trajectory, of the human brain (Refs 46, 47). There are both unguided and guided approaches to generating brain organoids. The unguided brain organoid, the cerebral organoid, relies on spontaneous morphogenesis and the intrinsic signalling capacities of human iPSCs to mimic the developing brain. Therefore, single cerebral organoids often contain cells from different brain regions because of the heterogenous tissue populations (Ref. 47). Guided methodologies, on the other hand, utilise growth factors and small molecules to specify progenitor fate to generate spheroids, which can be fused to generate assembloids that can model the interactions between different brain regions, or brain region-specific organoids (Ref. 47). Numerous brain region-specific organoids have been generated, including cortical, hypothalamic, midbrain, pituitary and hippocampal organoids (Refs 39, 46, 47, 48, 49).

The following sections aim to synthesise recent findings using organoids to model and recapitulate the primary pathological components of AD, namely Aβ and tau aggregation, neuroinflammation, mitochondrial dysfunction and oxidative stress, and synaptic and circuitry dysregulation. Additionally, the current limitations and future applications of the 3D modelling system will be discussed.

Modelling of AD pathology using human brain organoids

Brain organoids can recapitulate the cellular diversity, gene expression patterns and spatial organisation of the prenatal human brain. Consequently, they are a useful model to study complex cellular interactions and processes. The utilisation of the brain organoid model system has demonstrated several advantages over other model systems in terms of reconstructing the AD landscape of the human brain as closely as possible and has yielded new insights into the pathological mechanisms of the disease. For example, although the sAD phenotype is unable to be modelled in transgenic animals, one study showed that in a brain organoid model chemical induction with the molecule aftin-5 resulted in a time-dependent increase in Aβ production and the Aβ42/40 ratio as seen in sAD, suggesting that non-endogenous causes of sAD can be studied in a brain organoid system (Ref. 50). Furthermore, the tighter, spherical cytoarchitecture of brain organoids limits Aβ diffusion, allowing for aggregation and plaque formation to occur, while also exhibiting concomitant NFT pathology, both of which are absent in 2D AD models (Ref. 43). Additionally, the cellular organisation in brain organoids is more representative of the in vivo brain structure, with cortical layer differentiation being observed in organoids, which cannot be achieved in 2D cultures. The spherical nature of brain organoids thus facilitates a wider array of multidirectional cellular interactions (Refs 51, 52, 53). Another advantage of the brain organoid model over 2D cultures is its usefulness to study the neuroinflammatory component of AD through co-culturing with microglia (Ref. 54). In the 3D co-culture model microglia are able to penetrate and disperse within the organoid in a manner more closely resembling the human microenvironment which promotes their development and maturation (Refs 53, 54), whereas 2D-cultured microglia retain a foetal transcriptomic signature (Ref. 55). This further creates an environment to investigate neuronal–glial interactions in organoids and enables the opportunity to study the spatiotemporal progression of neuroinflammation.

In recent years, 3D culture systems, including brain organoids, have demonstrated clear potential of recapitulating elements of AD pathology, including the deposition of Aβ plaques and NFTs, elevated levels of phospho-tau (p-tau) and pro-inflammatory molecules and elements of mitochondrial dysfunction, oxidative stress and synaptic dysfunction (Table 1). In this section, we aim to provide an overview of the potential of brain organoids as a humanised model system of AD pathology.

Aβ

Choi *et al.* were the first group to utilise a 3D cell culture model to study the pathogenesis of AD (Ref. 56). They generated their 3D culture system using a human neural progenitor cell (ReN) line, engineered to express the fAD-causing *APP* Swedish (K670N/M671L) and London (V717I) mutations ($APP^{Swe/Lon}$) and/or the PS1ΔE9 mutation. At 6 weeks post differentiation, compared with healthy controls, their fAD 3D culture exhibited highly elevated levels of secreted Aβ40 and Aβ42, which are the most abundant and amyloidogenic Aβ species found in AD (Refs 56, 57). Aβ42, although less abundant than Aβ40 in human AD brains, is especially fibrillogenic, and Choi *et al.* observed an increased Aβ42/40 ratio in their fAD 3D culture (Ref. 56). Subsequent staining for insoluble Aβ deposits also revealed the presence of elevated extracellular Aβ aggregates in 6-week-old 3D cultures, indicating amyloid plaque-like deposition as seen in AD. Both levels of secreted Aβ and Aβ aggregates were reduced upon treatment with inhibitors of β-secretase and γ-secretase, which are involved in the proteolytic cleavage of APP into Aβ. Robust plaque-like pathology has since been reported in other studies using brain organoids with different fAD mutations (Refs 58, 59, 60). In a subsequent study, this group also generated 3D ReN cultures bearing mutations in the APP transmembrane domain, either I45F or I47F (Ref. 61). They found that the I45F mutation led to a drastic increase in the Aβ42/40 ratio which determined the higher aggregation propensity of Aβ, whereas a low Aβ42/40 ratio in the I47F brain organoids led to lower rates of aggregation. High Aβ42/40 ratios also correlated with increased cell death through elevated amounts of active caspase-3, a marker for cellular apoptosis (Ref. 61). Aβ accumulation was also studied in a hippocampal spheroid model by Pomeshchik *et al.*, using AD patient-derived iPSCs harbouring either the *APP* London (V717I) mutation or the *PSEN1* R278K mutation (Ref. 62). They observed elevated Aβ42/40 ratios in both AD spheroid models compared with control ones; however, only the hippocampal neurons with *APP* V717I, and not *PSEN1* R278K, exhibited a significantly higher intracellular β-sheet structure, indicative of increased protein aggregation. Furthermore, neurons only from the hippocampal spheroids with *APP* V717I displayed altered cell body size and neurite length, as well as a reduced number of action potential firings and a significantly more depolarised threshold (Ref. 62). Together, these results suggest that the different fAD mutations in *APP* compared with *PSEN1* trigger AD pathology in the hippocampus by mechanistically distinct pathways.

The differential effects of fAD mutations on Aβ accumulation were also examined by Arber *et al.* in patient cell-derived brain organoids, harbouring mutations in either *APP* or *PSEN1* (Ref. 63). They showed that the *APP* V717I mutation leads to altered processing of APP by γ-secretase, yielding skewed ratios of Aβ fragments of varying lengths. The resulting increased cleavage of Aβ38 and Aβ39 fragments may indicate that the canonical accumulation of Aβ42 species might not be the pathogenic trigger

https://doi.org/10.1017/erm.2022.40 Published online by Cambridge University Press

Table 1. Summary of 3D culture models of AD

Cell type/origin	Genetic background/treatment	AD-associated phenotypes and key findings	Reference
Synthetic 3D matrix culture			
Immortalised hNPC-derived neurons and astrocytes	Lentiviral transduction of *APP*$^{Swe/Lon}$/*PSEN1* ΔE9/*APP*$^{Swe/Lon}$ × *PSEN1* ΔE9	↑ Aβ extracellular deposits and insoluble aggregates ↑ p-tau-positive insoluble aggregates ↓ Amyloid and tau burden with β-secretase and γ-secretase inhibitors ↓ Tau deposition with GSK3 inhibitor	56
	Lentiviral transduction of *APP*$^{Swe/Lon}$/*PSEN1* ΔE9/*APP*$^{Swe/Lon}$ × *PSEN1* ΔE9 and *APP*^{Swe} × *APP* I45F or I47F	↑ Aβ42/40 correlates with ↑ levels of detergent-resistant amyloid species and p-tau accumulation I45F leads to ↑ Aβ42/40 and ↑ amyloid aggregation I47F leads to ↓ Aβ42/40 and undetectable amyloid aggregates	61
Triculture of immortalised hNPC-derived neurons and astrocytes with immortalised human microglia cells	Lentiviral transduction of *APP*$^{Swe/Lon}$	↑ Aβ and p-tau in 3D neuron + astrocyte cultures ↑ Neuroinflammatory cytokines (IL-6, IL-8, TNFα) and chemokines (CCL2, CCL5, CXCL10, CXCL12) Microglia in triculture cause retraction of neurites and reduced overall cell survival Microglia-related neurotoxicity is partially mediated by an IFN-γ- and TLR4-dependent pathway	80
Human cerebral organoids			
fAD patient-derived iPSCs	*PSEN1* A246E	↑ Aβ42/40 ratio, BTA-1 positive amyloid-like aggregates and apoptosis markers ↑ p-tau tangle-like deposits + NFT-like structures in cytoplasm and neurites	58[a]
	APP duplication	↑ Aβ soluble species, oligomers and aggregates ↑ Thioflavin-S + p-tau immunoreactivity ↑ Number of large endosomes resulting in ↑ Aβ processing	59
	APP^{Lon} (V717I) and *PSEN1* int4del/Y115H/M139V/M146I/R278I	APP V717I led to ↑ Aβ38/40 resulting in alternative pathology ↑ Aβ42/40 by all mutations except for R278I ↑ Aβ42/38 in all PSEN1 mutations except for Y115H PSEN1 int4del and Y115H lead to deficiency in γ-secretase activity	63
	PSEN1 M146V	↑ Proinflammatory signalling (IL-6 and TNFα) ↑ Expression of syndecan-3 resulted in ↑ Aβ42 deposition ↓ Aβ42 by treatment with heparin and heparinase-III ↓ Expression of MMP2 and MMP3 resulting in ↓ ECM remodelling	66[a]
	PSEN2 N141I	↑Aβ42 levels, Aβ42/40 ratio and apoptosis in AD organoids compared with isogenic controls *PSEN2* mutant organoids display asynchronous calcium transients and neuronal hyperactivity	92
sAD patient-derived iPSCs	APOE4 versus APOE3 homozygotes	APOE4 correlates with ↓ levels of full-length APP APOE4 ↑ p-tau levels and aggravates tau pathology APOE4 and AD status cause wide transcriptomic changes resulting in ↑ amyloid processing and RNA metabolism dysregulation	69[a]
	n/a	HDAC6 is ↑ in AD organoids resulting in ↑ pathological tau HDAC6 inhibition leads to ↓ in total and p-tau in AD organoids	74
	PITRM1−/− knockout using CRISPR/Cas9	PITRM1−/− organoids exhibit ↑ Aβ40, Aβ42, Aβ42/40 and p-tau PITRM1−/− organoids exhibit ↑ UPRmt transcripts = cellular stress Inhibiting UPRmt results in ↑ Aβ42/40, p-tau and impaired mitochondrial clearance Treatment with NMN ameliorates AD-associated phenotype	86[a]
hiPSC	CRISPR/Cas9 genome editing *APP* duplication organoids *APOE4* microglia	APOE4 induces pro-inflammatory phenotype in microglia and impairs Aβ uptake APOE4 organoids have ↑ Aβ aggregates and p-tau levels compared with APOE3	67[a]
		AD organoids display ↑ action potential firing rates and shorter neurites	88

(*Continued*)

Table 1. (*Continued.*)

Cell type/origin	Genetic background/treatment	AD-associated phenotypes and key findings	Reference
	CRISPR/Cas9 genome editing *APP*^{Swe} (K670N/M671L) and *PSEN1* M146V	↑ VGLUT1 and decreased VGAT staining in AD organoids = hyperexcitability and impaired neuronal inhibition	
	CRISPR/Cas9 genome editing *APP*^{Swe} (K670N/M671L) and *PSEN1* M146V	AD neuronal cultures and organoids exhibit hypersynchronous neuronal network burst activity NitroSynapsin (NMDAR inhibitor) normalises firing rate and burst activity NitroSynapsin protects dendrites and presynaptic endings in AD mouse models	92
	Chemical induction of Aβ using Aftin-5 – sAD phenotype	Aftin-5 results in ↑ Aβ42 production and extracellular deposition, leads to ↑Aβ42/40 ratio Soluble Aβ40 and Aβ42 ↑ in a time-dependent manner	50
Down syndrome patient-derived iPSCs	Trisomy 21 (T21) and *APP* duplication	T21 organoids show ↑ proportion of BACE2 non-amyloidogenic products Aβ 1–19, 1–20, 1–34 compared with control or APP duplication organoids Deletion of third copy of BACE2 results in significant ↓ in levels of BACE2 non-amyloidogenic products and induces amyloid plaque deposition in T21 organoids	60[a]
3D hydrogel-based cell cultures			
Primary cortical human astrocytes	None (AD phenotype generated through treatment with Aβ42)	Aβ42 ↓ the number of proliferating progenitors and their neurogenic capacity KYNA mediates the anti-proliferative and anti-neurogenic effects of Aβ42 IL-4 ↓ KYNA concentration which rescues the Aβ42-mediated ↓ in neurogenesis	77
3D astrocyte spheroids			
Generated from human iPSCs; subsequently co-cultured with isogenic cortical spheroids	None (AD phenotype generated through treatment with Aβ42 oligomers)	Aβ42 treatment induces ROS production and oxidative stress Aβ42 ↑ secretion of VEGF-A, implicated in BBB permeation Aβ42 ↑ inflammatory IL-6 and TNFα secretion Co-culturing cortical spheroids with astrocyte spheroids is more protective against Aβ42 toxicity, compared with cortical spheroids without co-culture	78
3D hippocampal spheroids			
Generated from fAD patient-derived iPSCs	*APP*^{Lon} (V717I) and *PSEN1* R278K	↑ Aβ42, Aβ42/40 ratio in both *APP* and *PSEN1* spheroids ↑ p-tau in *APP* spheroids compared with controls *APP* but not *PSEN1* spheroids exhibit altered size of soma and neurites and ↓ number of action potentials *APP* but not *PSEN1* spheroids display ↑ intracellular β-sheet structures	62

Aβ, amyloid-β; AD, Alzheimer's disease; APOE, apolipoprotein E; APP, amyloid precursor protein; BBB, blood–brain barrier; ECM, extracellular matrix; fAD, familial Alzheimer's disease; GSK, glycogen synthase kinase; HDAC, histone deacetylase; hNPCs, human neural precursor cells; IL, interleukin; IFN, interferon; iPSCs, induced pluripotent stem cells; KYNA, kynurenic acid; MMP, matrix metalloproteinase; n/a, not available; NFT, neurofibrillary tangle; NMDAR, *N*-methyl-D-aspartate receptor; PSEN, presenilin; p-tau, phosphorylated-tau; ROS, reactive oxygen species; sAD, sporadic Alzheimer's disease; TNF, tumour necrosis factor.
Human cerebral organoids contain numerous cell types including neural stem cells, intermediate neural progenitors and neurons.
[a]Denotes the presence of astrocytes in human cerebral organoids.

and that alternative APP-associated mechanisms underlie the pathogenicity of this mutation (Ref. 64). On the other hand, their panel of *PSEN1* mutations revealed a reduced carboxypeptidase activity of γ-secretase, favouring the production of longer Aβ fragments, which are proposed to be more amyloidogenic. Conversely, a study by Alić *et al.* using iPSC-derived cerebral organoids from a Down syndrome (DS) patient with trisomy 21, showed the presence of a potential mechanism that could be involved in the prevention or delay of AD dementia in individuals with DS (Ref. 60). DS patients carry a third copy of the *APP* gene on chromosome 21 which causes early-onset AD in over 40% of individuals over the age of 50 (Ref. 65). However, Alić *et al.* demonstrated that the presence of a third copy of another gene, *BACE2*, on chromosome 21 resulted in increased cleavage of APP into shorter, non-amyloidogenic peptides 1–19, 1–20 and 1–34, and therefore attenuation of AD pathology (Ref. 60). These organoids also displayed a higher ratio of non-amyloidogenic/amyloidogenic Aβ products, compared with isogenic euploid organoids as well as AD organoids harbouring an *APP* duplication mutation only. However, deletion of the third *BACE2* gene copy completely reversed these effects and led to increased amyloid plaque staining instead (Ref. 60), suggesting that a higher *BACE2* copy number resulted in alternate *APP* processing which could delay the onset of AD in some individuals with DS, according to the authors (Ref. 60).

In a study by Yan *et al.*, the *PSEN1* mutation M146V was shown to affect the expression of extracellular matrix (ECM)-modulating proteins in brain organoids, such as matrix metalloproteinases (MMPs) and syndecan-3, which can influence Aβ pathology (Ref. 66). MMP2, which functions in ECM remodelling and axonal regeneration, and MMP3, which can degrade Aβ, were both downregulated in this model, indicating that dysfunction in ECM regulatory processes could be a factor in AD pathogenesis. Conversely, syndecan-3, which has been associated with plaque

https://doi.org/10.1017/erm.2022.40 Published online by Cambridge University Press

formation, was detected at higher levels. Interestingly, treatment with heparin or heparinase-III, anti-inflammatory molecules, was shown to reduce Aβ42 levels in their brain organoids (Ref. 66).

The effects of *APOE* genotype on Aβ accumulation have also been examined using iPSC-derived brain organoids. Lin *et al.* showed that in organoids expressing *APOE4* there is a robust increase in Aβ42 compared with *APOE3* expressing brain organoids, although this difference became significant first at 6 months post differentiation (Ref. 67). It is noteworthy that the organoids used by Lin *et al.* were generated from wild-type (WT) iPSCs and did not carry any fAD-causing mutations, which would have accelerated the production and accumulation of Aβ. Instead, they relied on a longer culture period for their observations and the effects on Aβ accumulation were a consequence of *APOE* genotype alone, which highlights the roles of *APOE4* as a genetic risk factor for late-onset AD. They also found that the *APOE4* genotype correlated with higher Aβ42 secretion, as well as an increased number of early endosomes in iPSC-derived neuronal cultures. Higher numbers of early endosomes have been reported in the brains of AD patients and have been linked to increased β-secretase processing of APP, generating Aβ precursors (Refs 59, 68). On the other hand, a study by Zhao *et al.* using iPSCs derived from AD patients showed that AD status (disease versus healthy) determined Aβ accumulation, as opposed to *APOE* genotype (*e3* versus *e4*) (Ref. 69). They did, however, also report that *APOE4* genotype was associated with lower levels of full-length APP. Although their findings appear to contradict the ones made by Lin *et al.*, Zhao *et al.* used culture times of only up to 12 weeks which could be insufficient time to study the contribution of late-onset risk factors to AD pathology. Instead, they used AD patient-derived cells, which could explain why they concluded that Aβ accumulation was determined by AD status rather than *APOE* genotype within their culture timespan. Furthermore, their use of enzyme-linked immunosorbent assay instead of western blot means that they could have detected Aβ sooner because of its secretion into the media preceding the formation of tissue-positive inclusions.

Tau

Tau is a protein abundantly expressed in neurons, where it primarily functions in stabilising the microtubule network in neuronal cell bodies and axons and facilitating axonal transport. In the adult human brain tau is present in six isoforms which differ in the number of amino-terminal inserts (0N, 1N, 2N) and carboxy-terminal repeats (3R, 4R) in the mRNA of the protein (Refs 70, 71). In AD all six isoforms are found in hyperphosphorylated tangles, in contrast to other tauopathies where certain isoforms are prevalent, making it an important distinction when modelling tau pathology in vitro (Ref. 72). However, 2D iPSC-derived neuronal cultures predominantly express the embryonic 0N3R isoform with little to no expression of the other isoforms, owing to their immature state and underlying the inability of the system to recapitulate AD-associated tau pathology (Refs 43, 71). On the other hand, 3D culture systems enhance neuronal maturation and have shown expression of all six tau isoforms, creating a more accurate picture of tau pathology in AD.

3D models do in fact show robust tau pathology with elevated levels of phosphorylated tau at residues Ser199/Ser202/Thr205, as well as Ser396/Ser404, which are indicators of AD-associated tau hyperphosphorylation (Refs 56, 58, 73). Additionally, Gallyas silver staining (Ref. 56) and thioflavin-S labelling (Ref. 59) of fAD brain organoids have revealed the presence of tau-positive NFT-like insoluble inclusions in the cytoplasm and neurites. The accumulation of tau has further been associated with high Aβ42/40 ratios, whereby an increase in the Aβ42/40 ratio correlates with increased levels of p-tau, total tau and insoluble tau inclusions in 3D culture models (Ref. 61). Notably, treatments with a γ-secretase modulator, which specifically reduces the Aβ42/40 ratio, lead to a decrease in p-tau levels (Ref. 61), which is also observed after treatments with β-secretase and γ-secretase inhibitors. Inhibition of glycogen synthase kinase 3 (GSK3) also shows a marked reduction in p-tau, independent of Aβ levels, implicating it as an effector of tau pathology downstream of Aβ (Ref. 56).

p-tau accumulation has been found to be modulated by the levels of histone deacetylase 6 (HDAC6) in the brain of the ADLP^{APT} mouse (5XFAD::JNPL3) AD model (Ref. 74). Acetylated tau has been shown to be more aggregation-resistant, and acetylation at key sites competes with phosphorylation, preventing pathological changes in tau (Ref. 74). HDAC6 deacetylates these tau residues, increasing the susceptibility to tangle formation. Additionally, HDAC6 is elevated in AD post-mortem brain tissue (Ref. 75), as well as in AD brain organoids, indicating it could be a pathological driver in AD. Pharmacological inhibition of HDAC6 in AD brain organoids has shown a reduction in both p-tau and total tau (Ref. 74), suggesting its potential as a putative drug target in AD.

APOE genotype has also been linked to tau levels. *APOE4* brain organoids exhibit higher levels of p-tau at Ser202/Thr205 compared with *APOE3* brain organoids (Ref. 67). This has been observed for both soluble and insoluble p-tau, suggesting *APOE4* could predispose to tangle formation. Furthermore, these elevations of p-tau in *APOE4* brain organoids have been shown to correlate directly to ApoE4 protein levels, as opposed to AD status only (Ref. 69), implicating a possible causal relationship. However, it is unclear whether this effect is directly caused by *APOE4* or secondary to impaired clearance of Aβ from the brain in *APOE4* carriers.

Neuroinflammation

The presence and accumulation of Aβ and tau toxic species stimulates the sustained secretion of pro-inflammatory molecules in the central nervous system, causing further tissue damage and exacerbating the cognitive decline in AD. Although microglia are the primary cell type involved in inflammatory responses, neurons and astrocytes can trigger the signalling cascades that lead to microglial activation (Ref. 76). In their 3D model, bearing the *PSEN1* M146V mutation and lacking microglia, Yan *et al.* showed that Aβ42 accumulation induced higher expression of TNFα and IL-6, two pro-inflammatory cytokines which are elevated in the brains of AD patients and have been linked to declining cognitive abilities (Ref. 66). The authors note that the elevation of these cytokines could have been because of the presence of reactive astrocytes having neurotoxic effects, but they did not explicitly investigate the roles of astrocytes in their AD model. They also observed increased secretion of lactate dehydrogenase (LDH) in their brain organoids, indicating higher cytotoxic stress and apoptosis, which could be associated with Aβ42-mediated pro-inflammatory signalling. Treatment with heparin, an anti-inflammatory molecule, was shown to increase cell viability, whereas treatments with heparinase-III and *N*-[*N*-(3,5-difluorophenacetyl)-l-alanyl]-*S*-phenylglycine *t*-butyl ester (DAPT), a γ-secretase inhibitor, reduced LDH levels and promoted cell survival by reducing Aβ42 levels (Refs 12, 66). Increased neuronal survival through anti-inflammatory molecule treatments demonstrates the detrimental, cytotoxic effects of inflammation in AD. Treatment with another anti-inflammatory cytokine, IL-4, has also been shown to promote cell viability and in particular

https://doi.org/10.1017/erm.2022.40 Published online by Cambridge University Press

increase the proliferative capacity and neurogenic potential of neural progenitor cells in 3D culture models (Ref. 77). Neurogenesis is critically impaired in AD, which further correlates with decreased cognitive performance. It has been observed that reduced neurogenesis is associated with increased production of kynurenic acid (KYNA), secondary to higher Aβ accumulation (Ref. 77). IL-4, on the other hand, upregulates neurogenesis and progenitor proliferation by suppressing KYNA production. These findings suggest that neuroinflammation not only exacerbates neuronal damage and death but also prevents the limited neuronal regeneration in AD.

The presence of Aβ oligomers has also been shown to upregulate the expression of vascular endothelial growth factor A (VEGF)-A in an astrosphere model (Ref. 78). VEGF-A primarily stimulates endothelial cell growth during blood vessel formation and can increase the permeability of endothelial cell layers during vascular remodelling. In AD, elevated levels of astrocyte-derived VEGF-A can result in increased permeability of the blood–brain barrier (BBB), leading to the extravasation of leucocytes from the peripheral bloodstream into the brain parenchyma (Ref. 79). This, in turn, can lead to further inflammatory signalling by the peripheral immune cells and increased neurotoxic stress and damage.

To study the role of microglia in neuroinflammation, Park *et al.* generated a triculture system using a 3D microfluidic platform (Ref. 80). Exogenous microglia migrated into a central chamber, containing their neuronal/astrocytic 3D cultures which bore the *APP*$^{Swe/Lon}$ mutation, and successfully penetrated and dispersed throughout them, mimicking the in vivo cellular environment. Park *et al.* showed that the 3D neuronal/astrocytic AD models secreted elevated levels of pro-inflammatory molecules such as the chemokine CCL2, as well as TNFα and interferon-γ, compared with controls (Ref. 80). The secretion of these molecules, primarily by activated astrocytes, induced the migratory phenotype in microglia, together with morphological changes consistent with an activated state of the microglia. Furthermore, microglia activation was observed to occur simultaneously to astrogliosis in the 3D AD culture, as seen by an increase in astrocytic glial fibrillary acidic protein (GFAP) staining (Ref. 80). The presence of the activated microglia in the AD cultures induced significant upregulation of pro-inflammatory markers compared with AD cultures lacking microglia. These included IL-6, IL-8 and TNFα, as well as chemokines CCL2, CCL5, CXCL10 and CXCL12, implicating microglia as widespread inflammatory mediators in AD (Ref. 80). Additionally, the 3D cultures containing microglia exhibited increased cellular and tissue damage compared with ones without microglia, resulting in reduced neuronal and astrocytic density and surface area, as well as retraction of neurites. These findings suggest that microglia-mediated neuroinflammation is a major contributor to neuronal loss in AD and an important mechanism to the progression of AD pathology.

APOE genotype has also been shown to affect the phenotype and functions of microglia. Microglia harbouring the *e4* allele display altered transcriptional signatures, whereby genes related to cell movement and development are downregulated, and genes related to immunogenic activity are strongly upregulated (Ref. 67). This denotes a phenotypic shift to a more active, pro-inflammatory state of the microglia which could underlie a mechanism for AD pathogenesis in *APOE4* carriers. An *APOE4* genotype has also been associated with increased cholesterol biosynthesis and reduced lipid catabolism and clearance in both microglia and astrocytes (Ref. 81). This has been shown to occur in tandem with impaired lysosomal-mediated import and degradation in *APOE4* versus *APOE3* glia (Ref. 81) which can lead to accumulations in intracellular lipids, as well as APP cleavage products including Aβ (Ref. 82). Dysregulation of lipid metabolism and lysosomal dysfunction in neuroglia have both been implicated as pathological hallmarks of AD. Additionally, co-culturing *APOE4* microglia with AD brain organoids has revealed that these microglia exhibit altered morphologies in 3D culture, resulting in an impaired ability to sense extracellular Aβ, compared with *APOE3* microglia (Ref. 67). *APOE4* microglia also show significantly slower uptake of Aβ42 compared with *APOE3* microglia because of impaired phagocytosis. Consequently, AD brain organoids co-cultured with *APOE4* microglia exhibit more extracellular Aβ aggregates than ones containing *APOE3* microglia (Ref. 67). This suggests that expression of *APOE4* in microglia dysregulates the homoeostatic machinery of the cells, and the impaired clearance of Aβ species triggers further sustained neurotoxic pro-inflammatory signalling.

Mitochondrial dysfunction and oxidative stress

Mitochondrial dysfunction and overproduction of ROS are hallmarks of various neurodegenerative diseases including AD. It has been reported that mitochondrial bioenergetics are disrupted in the brains of AD patients, leading to glucose hypometabolism and reduction in adenosine triphosphate (ATP) synthesis because of impaired oxidative phosphorylation processes (Ref. 83). Additionally, inefficiencies in the electron transport chain (ETC) machinery have been shown to increase the production of ROS, which are cytotoxic in high amounts, resulting in cell death. Additionally, ROS have been found to be elevated in brain organoids, secondary to elevated levels of Aβ42 (Refs 78, 84). Thus, understanding the principles behind mitochondrial dysfunction could elucidate a key step in the pathogenesis of AD.

One mitochondrial enzyme associated with AD-like pathology is pitrilysin metallopeptidase 1 (PITRM1). PITRM1 degrades the mitochondrial targeting sequence of peptides, priming them for mitochondrial import across the inner membrane, and is necessary for the processing and maturation of mitochondrial proteins (Ref. 85). It has also been shown to degrade Aβ peptides and generate short, non-fibrillogenic fragments. Loss of function of PITRM1 can therefore lead to accumulation of peptides within the mitochondrial matrix, including Aβ, which can disrupt the mitochondrial membrane potential and interfere with the ETC, causing mitochondrial dysfunction (Ref. 85). A study by Pérez *et al.* demonstrated the effects of PITRM1 loss in AD by generating homozygous knock-out brain organoids for the *PITRM1* gene (Ref. 86). Initially, they observed that PITRM1 loss resulted in differential gene expression, compared with isogenic brain organoids, which affected normal mitochondrial function and oxidative phosphorylation in both neurons and glia. Additionally, PITRM1-deficient brain organoids exhibited increased Aβ40, Aβ42 and Aβ42/40, as well as detectable plaque pathology and tau hyperphosphorylation (Ref. 86). Levels of cleaved caspase-3 were also elevated, indicating increased cell death. These data suggest that PITRM1 loss can induce the major neuropathological features of AD and could represent a pathogenic mechanism in some AD cases.

Another significant observation made by Pérez *et al.* was that PITRM1 loss in brain organoids induced a dramatic upregulation of genes involved in the mitochondrial unfolded protein response (UPRmt) (Ref. 86). UPRmt, part of the integrated stress response (ISR), has been shown to induce the autophagy and clearance of defective mitochondria and can therefore be protective against mitochondrial damage (Ref. 85). Inhibiting the ISR, in turn, led to an increase in Aβ42/40 and p-tau, as well as reduced mitochondrial clearance, which has been implicated in AD pathogenesis. Conversely, treatment of the PITRM1 knock-out brain organoids with nicotinamide mononucleotide (NMN), a nicotinamide

https://doi.org/10.1017/erm.2022.40 Published online by Cambridge University Press

adenine dinucleotide (NAD+) precursor, enhanced mitochondrial clearance and reduced Aβ42/40 and p-tau levels (Ref. 86), suggesting that targeting mitochondrial function and turnover could be a potential therapeutic strategy for AD.

Synaptic and network dysfunction

Disruption of normal synaptic function and connectivity is another hallmark of AD, initiated during the early stages of disease pathogenesis and underlying cognitive decline. It is believed that the small Aβ oligomers, as opposed to monomers or fibrils, are the major culprit behind synaptic dysfunction (Ref. 87). Aβ oligomers are known to localise to the postsynaptic terminals of excitatory neurons and act on *N*-methyl-D-aspartate receptors (NMDARs), inducing neurons into a hyperexcitable state and disrupting normal action potential firing patterns and long-term potentiation processes. However, newer models and approaches are now providing more evidence, allowing an increased understanding of the scope of synaptic dysfunction in AD.

A study by Ghatak *et al.* using brain organoids with either the *PSEN1* M146V or *APP* Swedish mutation, showed that the AD brain organoids displayed increased action potential firing rates compared with WT brain organoids, indicating neuronal hyperexcitability because of the presence of AD mutations (Ref. 88). Additionally, they found that the neurons in the AD brain organoids had shorter neurites and exhibited increased staining for vesicular glutamate transporter 1 (VGLUT1) and decreased staining for vesicular γ-aminobutyric acid (GABA) transporter. These data suggest that excitatory glutamate signalling is elevated in AD, while inhibitory GABA signalling is reduced, contributing to another pathological aspect of AD known as excitotoxicity. Increased concentrations of extracellular glutamate have been reported in AD and are associated with aberrant neuronal firing and the activation of calcium-dependent apoptotic pathways (Refs 89, 90). Similarly, using 2D AD neuronal cultures Ghatak *et al.* also showed that the proportion of glutamatergic neurons was higher whereas that of GABAergic neurons was lower, compared with WT cultures (Ref. 88). However, in a subsequent study it was shown that administration of an NMDAR antagonist, NitroSynapsin, was able to ameliorate the hyperexcitable phenotype of neurons in AD brain organoids by normalising glutamate-induced neuronal firing (Ref. 91). Notably, blocking the hyperactivity of extra-synaptic NMDARs was shown to decrease AD-related pathological signalling (Refs 89, 91), highlighting the possible pathological mechanism of hyperexcitability and proposing a putative therapeutic strategy against excitotoxicity in AD.

Similarly, Yin and VanDongen used AD patient iPSC-derived cerebral organoids with the *PSEN2* N141I mutation to study network activity in AD through fluorescent calcium imaging (Ref. 92). They showed that the calcium transients in their AD organoids were asynchronous but displayed a higher activity compared with isogenic control organoids, while also exhibiting a significantly higher amplitude and firing rate. Together, the results of Ghatak *et al.* and Yin and VanDongen demonstrate that disruptions in the normal function of γ-secretase, caused by fAD mutations in either *PSEN1* or *PSEN2,* lead to downstream dysregulations in synaptic and network connectivity.

Current challenges and future directions

Evidently, 3D brain organoid systems provide great advantages over 2D cultures, exhibiting both Aβ and NFT pathology, synaptic and mitochondrial dysfunction, and neuroinflammation along with cell-to-cell interactions. As such, brain organoids have provided increased understanding of AD pathophysiology. However, there is still much progress that can be made to allow brain organoids to encapsulate the full aetiology of AD, including, but not limited to, integrating neuron–microglia interactions into the system, incorporating a vascular system, and recapitulating the age-related phenotype of AD.

Notably, the most commonly used AD brain organoids contain neuronal progenitor cells and neurons, which are derived from the ectoderm but lack microglial cells, which are derived from the mesoderm (Ref. 93). As previously described, microglia have important immunological roles in AD development with their activation resulting in the release of inflammatory mediators which cause neuronal death/injury and synaptic damage (Ref. 93). More recently, it has been shown that AD brain organoids containing microglia can be developed via co-culturing methods which involve co-culturing microglial cells with brain organoids and changing the culture formulations (Ref. 93). There are a number of microglia differentiation protocols which allow microglia to be generated from iPSCs (Ref. 94). The first protocol for microglia differentiation from iPSCs was published in 2016 by Muffat and colleagues who cultivated human embryonic stem cells and iPSCs and tested for yolk-sac myelogenesis markers (e.g. VE-cadherin, PU.1 and CD41) which are vital for microglia maturation and viability. Embryoid bodies positive for these markers were further cultivated and differentiated into microglia by employing CSF1 and IL-34 (Refs 94, 95). More recently published protocols involve various culturing techniques including generation of microglia-like cells from iPSCs (Ref. 54); from myeloid progenitors (Ref. 96); from embryonic-like MYB-independent precursors (Ref. 97); via co-culture of iPSCs with astrocytes (Ref. 98); using macrophage differentiation as an intermediate step and mimicking the mesoderm specification (Ref. 99); by differentiation of iPSCs to primitive macrophage precursors (Refs 100, 101) and by changing the culture medium to include factors such as IL-34, transforming growth factor-β1, macrophage colony-stimulating factor (M-CSF) and CD200 (Ref. 102). However, the application of these differentiation protocols to develop 3D brain organoids containing microglia proves more challenging and only a limited number of studies have been able to develop a 3D system which involves the interaction between microglia and neurons (Ref. 94). Muffat and colleagues demonstrated that in 2D culture microglia maintain their 'resting' rounded morphology, however, when cultured under 3D conditions they displayed an 'activated' ramified morphology (Refs 94, 95). Supporting this, both Abud *et al.* and Brownjohn *et al.* demonstrated that when human microglia-like cells are cultured with brain organoids they migrate into the organoid and display a highly ramified morphology. In both studies, the microglia were able to survive for several weeks (Refs 54, 94, 100).

Additionally, brain organoids lack complete vascularisation which is necessary to encapsulate the in vivo environment of the brain (Ref. 103). This limits their application for the study of angiogenesis and cerebrovascular disorders and has important implications for the study of AD as it means that brain organoids also lack a BBB which has been shown to be dysfunctional in AD before neurodegeneration occurs (Refs 104, 105). Although attempts have been made to reproduce the BBB in organoids via co-culture of pericytes, astrocytes and brain microvascular endothelial cells, there has been difficulty in modulating the BBB tight junctions which hinders the system from being fully functional (Refs 105, 106, 107). However, it has been shown that brain organoids derived from human embryonic stem cells which were engineered to express human Ets variant transcription factor 2 (ETV2) were able to form vascular-like structures and several BBB characteristics including increased expression of tight junctions, trans-endothelial electrical resistance and nutrient transporters (Ref. 108). Additionally, brain organoids have been

https://doi.org/10.1017/erm.2022.40 Published online by Cambridge University Press



Fig. 1. Overview of AD pathology modelled by human brain organoids. A*β*, amyloid-*β*; AD, Alzheimer's disease; AP, action potential; APP, amyloid precursor protein; HDAC, histone deacetylase; IL, interleukin; IFN, interferon; hiPSCs, human induced pluripotent stem cells; KYNA, kynurenic acid; MMP, matrix metalloproteinase; NFT, neurofibrillary tangle; PSEN, presenilin; p-tau, phosphorylated-tau; ROS, reactive oxygen species; TNF, tumour necrosis factor; VEGF, vascular endothelial growth factor; VGAT, vesicular GABA transporter; VGLUT, vesicular glutamate transporter. Figure created with BioRender.com.

vascularised by co-culture with human umbilical vascular cells resulting in expression of P-glycoprotein, a BBB marker, improvements of the hypoxic state of the organoids, higher numbers of spontaneously active neurons and increased growth of the organoids (Refs 109, 110). These findings provide a valid physiological representation of the brain and may allow for a greater understanding of the role of the BBB and vasculature in AD.

Specifically for the application of brain organoids to AD, a critical obstruction is that iPSC-derived neural cells exhibit a transcriptional profile analogous to the prenatal brain (Refs 93, 103, 111). Previously, it has been reported that brain organoids exhibit internal cellular apoptosis and volume shrinkage after 180 days of culture as, without a vascular system, nutrients and oxygen cannot enter the innermost regions of the organoid (Refs 93, 112). It is therefore challenging to recapitulate the age-related phenotypes of AD in brain organoids (Ref. 93). This poses a major limitation as ageing is the core risk factor for developing AD meaning that current brain organoids do not sufficiently simulate the real AD brain (Refs 93, 103, 112). Telomere shortening has previously been used to induce ageing-specific phenotypes such as a reduced number of dendrites and increased mitochondrial stress in iPSCs; however, this has not yet been translated to organoid development (Ref. 113). Furthermore, overexpression of progeria, a variant of the lamin A/C gene which causes premature ageing, in iPSC-derived dopaminergic neurons resulted in dendrite degeneration, the accumulation of ROS and DNA damage (Ref. 114). Recently, researchers have been able to grow brain organoids, harbouring the most common amyotrophic lateral sclerosis and frontotemporal dementia mutations, for 240 days which has not previously been possible (Ref. 115). This provides hope that age-related phenotypes will soon be able to be translated from iPSC models to brain organoids, further increasing their validity as a model of AD.

Transplantation of brain organoids represents an attractive option for overcoming such limitations, including the involvement of neuron–microglia interactions and vasculature (Ref. 116). Numerous studies have demonstrated that organoids can be successfully transplanted into the mouse cortex leading to increased neurogenesis, cell survival and neuronal differentiation and maturation (Refs 117, 118, 119). For instance, transplanted brain organoids have been shown to be vascularised by endothelial cells from the host mouse brain, facilitating functional synaptic connectivity and neuronal activity between the transplanted organoid and the host brain (Ref. 118). Additionally, whole-cell patch-clamp recordings have demonstrated that brain organoids undergo functional maturation after transplantation into the mouse brain (Ref. 120). To date, the majority of brain organoid transplantation studies have focused on post-stroke repair (Refs 119, 121) and no study has yet focused on organoid transplantation for AD therapeutics. However, with further research transplantation of organoids presents a promising approach to allow further encapsulation of the in vivo human brain for AD research.

Brain organoids provide attractive alternative avenues for disease modelling and have enormous potential for drug screening and precision medicine applications. However, the advantage of organoids having the capacity to model complex processes contradicts the simple molecular assays typically used in targeted drug discovery (Ref. 122). Thus, it is more likely that organoids will be valuable at the target identification stage, increasing understanding of the molecules and/or pathways that modulate the progression of AD, or in the later stages of lead development where the aim is to select the most biologically active compound (Ref. 122). It is possible that in the future a patient's own cells could be reprogrammed to grow an organoid which could be used to assess which unique combination of drugs best suits their disease and allow clinicians to accurately predict the drug response in individual patients (Refs 105, 123). However, attempts to generate organoids derived from primary material have focused on epithelial tissue. Therefore, adapting the current patient-derived organoid

technology to model AD using non-epithelial tissues would come with numerous technical limitations and further development of high-throughput methods and culture conditions would be required (Refs 103, 105).

Conclusions

In summary, brain organoids recapitulate many features of the in vivo brain that cannot be achieved by cell and animal research. Brain organoids provide a useful model to study the mechanisms of AD pathology, including Aβ deposition, NFTs, neuroinflammation, oxidative stress, mitochondrial, synaptic and network dysfunction (Fig. 1). However, it is important to note that further research is required in order to fully encapsulate the whole pathology of some of these mechanisms, most notably developing co-culture methods to study the role of microglia in AD neuroinflammation pathology. AD brain organoids can be further developed, including incorporating BBB dysfunction and the ageing phenotype into these models. However, despite these required developments, brain organoids remain a useful tool for modelling AD pathogenesis and are likely to prove invaluable for drug screening and personalised medicine applications.

Financial support. The work in the Kang Lab and Berg Lab is supported by Development Trust Relevant Dementia Research Projects at Institute of Medical Sciences, University of Aberdeen

Conflict of interest. The authors declare no conflicts of interest.

References

1. **Nichols E *et al.*** (2022) Estimation of the global prevalence of dementia in 2019 and forecasted prevalence in 2050: an analysis for the global burden of disease study 2019. *The Lancet Public Health* **7**, 105–125.
2. **Wimo A *et al.*** (2017) The worldwide costs of dementia 2015 and comparisons with 2010. *Alzheimer's & Dementia* **13**, 1–7.
3. **Luengo-Fernandez R, Leal J and Gray A** (2015) UK research spend in 2008 and 2012: comparing stroke, cancer, coronary heart disease and dementia. *BMJ Open* **5**, e006648.
4. **DeTure MA and Dickson DW** (2019) The neuropathological diagnosis of Alzheimer's disease. *Molecular Neurodegeneration* **14**, 1–18.
5. **Friedrich RP *et al.*** (2010) Mechanism of amyloid plaque formation suggests an intracellular basis of Aβ pathogenicity. Proceedings of the National Academy of Sciences *of the United States of America* **107**, 1942–1947.
6. **Reitz C** (2012) Alzheimer's disease and the amyloid cascade hypothesis: a critical review. *International Journal of Alzheimer's Disease* **2012**, article ID 369808.
7. **Mucke L *et al.*** (2000) High-level neuronal expression of Aβ1–42 in wild-type human amyloid protein precursor transgenic mice: synaptotoxicity without plaque formation. *The Journal of Neuroscience* **20**, 4050–4058.
8. **Kitazawa M, Medeiros R and LaFerla FM** (2012) Transgenic mouse models of Alzheimer disease: developing a better model as a tool for therapeutic interventions. *Current Pharmaceutical Design* **18**, 1131–1147.
9. **Bloom GS** (2014) Amyloid-β and tau: the trigger and bullet in Alzheimer disease pathogenesis. *JAMA Neurology* **71**, 505–508.
10. **Hadjichrysanthou C *et al.*** (2020) The dynamics of biomarkers across the clinical spectrum of Alzheimer's disease. *Alzheimer's Research & Therapy* **12**, 1–16.
11. **Cline EN *et al.*** (2018) The amyloid-β oligomer hypothesis: beginning of the third decade. *Journal of Alzheimer's Disease* **64**, 567–610.
12. **Resnick SM *et al.*** (2010) Longitudinal cognitive decline is associated with fibrillar amyloid-beta measured by $^{[11C]}$PiB. *Neurology* **74**, 807–815.
13. **Shepherd C *et al.*** (2009) Variations in the neuropathology of familial Alzheimer's disease. *Acta Neuropathologica* **118**, 37–52.
14. **Janssen JC *et al.*** (2003) Early onset familial Alzheimer's disease. *Neurology* **60**, 235–239.
15. **Crous-Bou M *et al.*** (2017) Alzheimer's disease prevention: from risk factors to early intervention. *Alzheimer's Research & Therapy* **9**, Article number: 71.
16. **Chen C and Zissimopoulos JM** (2018) Racial and ethnic differences in trends in dementia prevalence and risk factors in the United States. *Alzheimer's & Dementia: Translational Research & Clinical Interventions* **4**, 510.
17. **Yamazaki Y *et al.*** (2019) Apolipoprotein E and Alzheimer disease: pathobiology and targeting strategies. *Nature Reviews Neurology* **15**, 501–518.
18. **Efthymiou AG and Goate AM** (2017) Late onset Alzheimer's disease genetics implicates microglial pathways in disease risk. *Molecular Neurodegeneration* **12**, 1–12.
19. **Jonsson T *et al.*** (2013) Variant of TREM2 associated with the risk of Alzheimer's disease. *The New England Journal of Medicine* **368**, 107–116.
20. **Griciuc A *et al.*** (2013) Alzheimer's disease risk gene CD33 inhibits microglial uptake of amyloid beta. *Neuron* **78**, 631–643.
21. **Lambert J-C *et al.*** (2009) Genome-wide association study identifies variants at CLU and CR1 associated with Alzheimer's disease. *Nature Genetics* **41**, 1094–1099.
22. **Tan L *et al.*** (2016) Effect of CLU genetic variants on cerebrospinal fluid and neuroimaging markers in healthy, mild cognitive impairment and Alzheimer's disease cohorts. *Scientific Reports* **6**, Article number: 26027.
23. **Sung P-S *et al.*** (2020) Neuroinflammation and neurogenesis in Alzheimer's disease and potential therapeutic approaches. *International Journal of Molecular Sciences* **21**, 701–721.
24. **Zhang F and Jiang L** (2015) Neuroinflammation in Alzheimer's disease. *Neuropsychiatric Disease and Treatment* **11**, 243.
25. **DiSabato D, Quan N and Godbout JP** (2016) Neuroinflammation: the devil is in the details. *Journal of Neurochemistry* **139**, 136.
26. **Leng F and Edison P** (2020) Neuroinflammation and microglial activation in Alzheimer disease: where do we go from here? *Nature Reviews Neurology* **17**, 157–172.
27. **Wang Q *et al.*** (2022) Baseline microglial activation correlates with brain amyloidosis and longitudinal cognitive decline in Alzheimer disease. *Neurology – Neuroimmunology and Neuroinflammation* **9**, e1152.
28. **Pascoal TA *et al.*** (2021) Microglial activation and tau propagate jointly across Braak stages. *Nature Medicine* **27**, 1592–1599.
29. **Liddelow SA *et al.*** (2017) Neurotoxic reactive astrocytes are induced by activated microglia HHS public access. *Nature* **10**, 481–487.
30. **González-Reyes RE *et al.*** (2017) Involvement of astrocytes in Alzheimer's disease from a neuroinflammatory and oxidative stress perspective. *Frontiers in Molecular Neuroscience* **10**, 427.
31. **Swardfager W *et al.*** (2010) A meta-analysis of cytokines in Alzheimer's disease. *Biological Psychiatry* **68**, 930–941.
32. **Drummond E and Wisniewski T** (2017) Alzheimer's disease: experimental models and reality. *Acta Neuropathologica* **133**, 155.
33. **Elder GA, Sosa MAG and de Gasperi R** (2010) Transgenic mouse models of Alzheimer's disease. *The Mount Sinai Journal of Medicine* **77**, 69.
34. **Gunawardena S and Goldstein L** (2001) Disruption of axonal transport and neuronal viability by amyloid precursor protein mutations in drosophila. *Neuron* **32**, 389–401.
35. **Sasaguri H *et al.*** (2017) APP mouse models for Alzheimer's disease preclinical studies. *The EMBO Journal* **36**, 2473–2487.
36. **Oddo S *et al.*** (2003) Triple-transgenic model of Alzheimer's disease with plaques and tangles: intracellular Abeta and synaptic dysfunction. *Neuron* **39**, 409–421.
37. **Hutton M *et al.*** (1998) Association of missense and 5′-splice-site mutations in tau with the inherited dementia FTDP-17. *Nature* **393**, 702–705.
38. **Smits LM *et al.*** (2019) Modeling Parkinson's disease in midbrain-like organoids. *Parkinson's Disease* **5**, 1–8.
39. **Sakaguchi H *et al.*** (2015) Generation of functional hippocampal neurons from self-organizing human embryonic stem cell-derived dorsomedial telencephalic tissue. *Nature Communications* **6**, 1–11.
40. **Ballabio C *et al.*** (2020) Modeling medulloblastoma in vivo and with human cerebellar organoids. *Nature Communications* **11**, 1–18.
41. **Penney J, Ralvenius WT and Tsai L-H** (2019) Modeling Alzheimer's disease with iPSC-derived brain cells. *Molecular Psychiatry* **25**, 148–167.
42. **Zhang Y *et al.*** (2013) Rapid single-step induction of functional neurons from human pluripotent stem cells. *Neuron* **78**, 785–798.
43. **Choi SH *et al.*** (2015) Recapitulating amyloid β and tau pathology in human neural cell culture models: clinical implications. *US Neurology* **11**, 102.
44. **Slanzi A *et al.*** (2020) In vitro models of neurodegenerative diseases. *Frontiers in Cell and Developmental Biology* **8**, 328.

https://doi.org/10.1017/erm.2022.40 Published online by Cambridge University Press

45. **Lancaster MA *et al.*** (2013) Cerebral organoids model human brain development and microcephaly. *Nature* **501**, 373–379.
46. **Qian X *et al.*** (2016) Brain-region-specific organoids using mini-bioreactors for modeling ZIKV exposure. *Cell* **165**, 1238–1254.
47. **Qian X, Song H and Ming G-L** (2019) Brain organoids: advances, applications and challenges. *Development* **146,** dev166074.
48. **Lancaster MA *et al.*** (2017) Guided self-organization and cortical plate formation in human brain organoids. *Nature Biotechnology* **35**, 659–666.
49. **Kadoshima T *et al.*** (2013) Self-organization of axial polarity, inside-out layer pattern, and species-specific progenitor dynamics in human ES cell-derived neocortex. *Proceedings of the National Academy of Sciences of the United States of America* **110**, 20284–20289.
50. **Pavoni S *et al.*** (2018) Small-molecule induction of Aβ-42 peptide production in human cerebral organoids to model Alzheimer's disease associated phenotypes. *PLoS ONE* **13**, e0209150.
51. **Bagley JA *et al.*** (2017) Fused cerebral organoids model interactions between brain regions. *Nature Methods* **14**, 743–751.
52. **Nascimento JM *et al.*** (2019) Human cerebral organoids and fetal brain tissue share proteomic similarities. *Frontiers in Cell and Developmental Biology* **7**, 303.
53. **Oliveira B, Çerağ Yahya A and Novarino G** (2019) Modeling cell–cell interactions in the brain using cerebral organoids. *Brain Research* **1724**, 146458.
54. **Abud EM *et al.*** (2018) iPSC-derived human microglia-like cells to study neurological diseases. **94**, 278–293.
55. **Ormel PR *et al.*** (2018) Microglia innately develop within cerebral organoids. *Nature Communications* **9,** Article number: 4167.
56. **Choi SH *et al.*** (2014) A three-dimensional human neural cell culture model of Alzheimer's disease. *Nature* **515**, 274.
57. **Chen G *et al.*** (2017) Amyloid beta: structure, biology and structure-based therapeutic development. *Acta Pharmacologica Sinica* **38**, 1205–1235.
58. **Gonzalez C *et al.*** (2018) Modeling amyloid beta and tau pathology in human cerebral organoids. *Molecular Psychiatry* **23**, 2363–2374.
59. **Raja WK *et al.*** (2016) Self-organizing 3D human neural tissue derived from induced pluripotent stem cells recapitulate Alzheimer's disease phenotypes. *PLoS ONE* **11**, e0161969.
60. **Alić I *et al.*** (2020) Patient-specific Alzheimer-like pathology in trisomy 21 cerebral organoids reveals BACE2 as a gene dose-sensitive AD suppressor in human brain. *Molecular Psychiatry* **26**, 5766–5788.
61. **Kwak SS *et al.*** (2020) Amyloid-β42/40 ratio drives tau pathology in 3D human neural cell culture models of Alzheimer's disease. *Nature Communications* **11**, Article number: 1377.
62. **Pomeshchik Y *et al.*** (2020) Human iPSC-derived hippocampal spheroids: an innovative tool for stratifying Alzheimer disease patient-specific cellular phenotypes and developing therapies. *Stem Cell Reports* **15**, 256–273.
63. **Arber C *et al.*** (2021) Familial Alzheimer's disease mutations in PSEN1 lead to premature human stem cell neurogenesis. *Cell Reports* **34**, 108615.
64. **Quartey MO *et al.*** (2021) The Aβ(1–38) peptide is a negative regulator of the Aβ(1–42) peptide implicated in Alzheimer disease progression. *Scientific Reports* **11**, 1–17.
65. **Holland AJ *et al.*** (1998) Population-based study of the prevalence and presentation of dementia in adults with down's syndrome. *The British Journal of Psychiatry* **172**, 493–498.
66. **Yan Y *et al.*** (2018) Modeling neurodegenerative microenvironment using cortical organoids derived from human stem cells. *Tissue Engineering* **24**, 1125–1137.
67. **Lin Y-T *et al.*** (2018) APOE4 causes widespread molecular and cellular alterations associated with Alzheimer's disease phenotypes in human iPSC-derived brain cell types. *Neuron* **98**, 1141–1154.
68. **Nixon RA** (2017) Amyloid precursor protein and endosomal–lysosomal dysfunction in Alzheimer's disease: inseparable partners in a multifactorial disease. *The FASEB Journal* **31**, 2729–2743.
69. **Zhao J *et al.*** (2020) APOE4 exacerbates synapse loss and neurodegeneration in Alzheimer's disease patient iPSC-derived cerebral organoids. *Nature Communications* **11**, Article number: 5540.
70. **Barbier P *et al.*** (2019) Role of tau as a microtubule-associated protein: structural and functional aspects. *Frontiers in Aging Neuroscience* **11**, 1–14.
71. **Arendt T, Stieler JT and Holzer M** (2016) Tau and tauopathies. *Brain Research Bulletin* **126**, 238–292.
72. **Cherry JD *et al.*** (2021) Tau isoforms are differentially expressed across the hippocampus in chronic traumatic encephalopathy and Alzheimer's disease. *Acta Neuropathologica Communications* **9**, 1–17.
73. **Moore S *et al.*** (2015) APP metabolism regulates tau proteostasis in human cerebral cortex neurons. *Cell Reports* **11**, 689–696.
74. **Choi H *et al.*** (2020) Acetylation changes tau interactome to degrade tau in Alzheimer's disease animal and organoid models. *Aging Cell* **19**, 1–13.
75. **Ding H, Dolan PJ and Johnson GVW** (2008) Histone deacetylase 6 interacts with the microtubule-associated protein tau. *Journal of Neurochemistry* **106**, 2119.
76. **Baxter PS *et al.*** (2021) Microglial identity and inflammatory responses are controlled by the combined effects of neurons and astrocytes. *Cell Reports* **34**, 108882.
77. **Papadimitriou C *et al.*** (2018) 3D culture method for Alzheimer's disease modeling reveals interleukin-4 rescues Aβ42-induced loss of human neural stem cell plasticity. *Developmental Cell* **46**, 85–101.
78. **Griffin K *et al.*** (2020) Human stem cell-derived aggregates of forebrain astroglia respond to amyloid beta oligomers. *Tissue Engineering* **26**, 527–542.
79. **Argaw AT *et al.*** (2012) Astrocyte-derived VEGF-A drives blood–brain barrier disruption in CNS inflammatory disease. *The Journal of Clinical Investigation* **122**, 2454.
80. **Park J *et al.*** (2018) A 3D human triculture system modeling neurodegeneration and neuroinflammation in Alzheimer's disease. *Nature Neuroscience* **21**, 941–951.
81. **TCW J *et al.*** (2022) Cholesterol and matrisome pathways dysregulated in astrocytes and microglia. *Cell* **185**, 2213–2233.e25.
82. **Zhang W *et al.*** (2022) Impairment of the autophagy–lysosomal pathway in Alzheimer's diseases: pathogenic mechanisms and therapeutic potential. *Acta Pharmaceutica Sinica B* **12**, 1019–1040.
83. **Wang W *et al.*** (2020) Mitochondria dysfunction in the pathogenesis of Alzheimer's disease: recent advances. *Molecular Neurodegeneration* **15**, 1–22.
84. **Eckert A, Schmitt K and Götz J** (2011) Mitochondrial dysfunction – the beginning of the end in Alzheimer's disease? Separate and synergistic modes of tau and amyloid-β toxicity. *Alzheimer's Research & Therapy* **3**, 15.
85. **Brunetti D *et al.*** (2021) Role of PITRM1 in mitochondrial dysfunction and neurodegeneration. *Biomedicines* **9**, 833.
86. **Pérez MJ *et al.*** (2020) Loss of function of the mitochondrial peptidase PITRM1 induces proteotoxic stress and Alzheimer's disease-like pathology in human cerebral organoids. *Molecular Psychiatry* **2020** 1–18.
87. **Marsh J and Alifragis P** (2018) Synaptic dysfunction in Alzheimer's disease: the effects of amyloid beta on synaptic vesicle dynamics as a novel target for therapeutic intervention. *Neural Regeneration Research* **13**, 616–623.
88. **Ghatak S *et al.*** (2019) Mechanisms of hyperexcitability in Alzheimer's disease hiPSC-derived neurons and cerebral organoids versus isogenic control. *eLife* **8**, 1–22.
89. **Wang R and Reddy PH** (2017) Role of glutamate and NMDA receptors in Alzheimer's disease. *Journal of Alzheimer's disease* **57**, 1041–1048.
90. **Hynd M, Scott H and Dodd P** (2004) Glutamate-mediated excitotoxicity and neurodegeneration in Alzheimer's disease. *Neurochemistry International* **45**, 583–595.
91. **Ghatak S *et al.*** (2020) NitroSynapsin ameliorates hypersynchronous neural network activity in Alzheimer hiPSC models. *Molecular Psychiatry* **26**, 5751–5765.
92. **Yin J and Vandongen AM** (2021) Enhanced neuronal activity and asynchronous calcium transients revealed in a 3D organoid model of Alzheimer's disease. *ACS Biomaterials Science and Engineering* **7**, 254–264.
93. **Bi F-C *et al.*** (2021) Optimization of cerebral organoids: a more qualified model for Alzheimer's disease research. *Translational Neurodegeneration* **10**, 1–13.
94. **Sabogal-Guáqueta AM *et al.*** (2020) Microglia alterations in neurodegenerative diseases and their modeling with human induced pluripotent stem cell and other platforms. *Progress in Neurobiology* **190**, 101805.
95. **Muffat J *et al.*** (2016) Efficient derivation of microglia-like cells from human pluripotent stem cells. *Nature Medicine* **22**, 1358–1367.
96. **Douvaras P *et al.*** (2017) Directed differentiation of human pluripotent stem cells to microglia. *Stem Cell Reports* **8**, 1516–1524.
97. **Haenseler W *et al.*** (2017) A highly efficient human pluripotent stem cell microglia model displays a neuronal-co-culture-specific expression profile and inflammatory response. *Stem Cell Reports* **8**, 1727–1742.

https://doi.org/10.1017/erm.2022.40 Published online by Cambridge University Press

98. **Pandya H *et al.*** (2017) Differentiation of human and murine induced pluripotent stem cells to microglia-like cells. *Nature Neuroscience* **20**, 753–759.
99. **Takata K *et al.*** (2017) Induced-pluripotent-stem-cell-derived primitive macrophages provide a platform for modeling tissue-resident macrophage differentiation and function. *Immunity* **47**, 183–198.
100. **Brownjohn PW *et al.*** (2018) Functional studies of missense TREM2 mutations in human stem cell-derived microglia. *Stem Cell Reports* **10**, 1294–1307.
101. **Garcia-Reitboeck P *et al.*** (2018) Human induced pluripotent stem cell-derived microglia-like cells harboring TREM2 missense mutations show specific deficits in phagocytosis. *Cell Reports* **24**, 2300–2311.
102. **McQuade A *et al.*** (2018) Development and validation of a simplified method to generate human microglia from pluripotent stem cells. *Molecular Neurodegeneration* **13**, 1–13.
103. **Papaspyropoulos A *et al.*** (2020) Modeling and targeting Alzheimer's disease with organoids. *Frontiers in Pharmacology* **11**, 396.
104. **Montagne A, Zhao Z and Zlokovic BV** (2017) Alzheimer's disease: a matter of blood–brain barrier dysfunction? *The Journal of Experimental Medicine* **214**, 3151.
105. **Cheah P-S, Mason JO and Ling KH** (2019) Challenges and future perspectives for 3D cerebral organoids as a model for complex brain disorders. *Neuroscience Research Notes* **2**, 1–6.
106. **Bergmann S *et al.*** (2018) Blood–brain-barrier organoids for investigating the permeability of CNS therapeutics. *Nature Protocols* **13**, 2827–2843.
107. **Lauschke K, Frederiksen L and Hall VJ** (2017) Paving the way toward complex blood–brain barrier models using pluripotent stem cells. *Stem Cells Development* **26**, 857–874.
108. **Cakir B *et al.*** (2019) Engineering of human brain organoids with a functional vascular-like system. *Nature Methods* **16**, 1169–1175.
109. **Shi Y *et al.*** (2020) Vascularized human cortical organoids (vOrganoids) model cortical development in vivo. *PLoS Biology* **18**, e3000705.
110. **Matsui TK *et al.*** (2021) Vascularization of human brain organoids. *Stem Cells* **39**, 1017–1024.
111. **Camp JG *et al.*** (2015) Human cerebral organoids recapitulate gene expression programs of fetal neocortex development. Proceedings of the National Academy of Sciences *of the United States of America* **112**, 15672–15677.
112. **Kelava I and Lancaster MA** (2016) Dishing out mini-brains: current progress and future prospects in brain organoid research. *Developmental Biology* **420**, 199–209.
113. **Vera E, Bosco N and Studer L** (2016) Generating late-onset human iPSC-based disease models by inducing neuronal age-related phenotypes through telomerase manipulation. *Cell Reports* **17**, 1184–1192.
114. **Miller JD *et al.*** (2013) Human iPSC-based modeling of late-onset disease via progerin-induced aging. *Cell Stem Cell* **13**, 691–705.
115. **Szebényi K *et al.*** (2021) Human ALS/FTD brain organoid slice cultures display distinct early astrocyte and targetable neuronal pathology. *Nature Neuroscience* **24**, 1542–1554.
116. **Song G *et al.*** (2021) The application of brain organoid technology in stroke research: challenges and prospects. *Frontiers in Cellular Neuroscience* **15**, 203.
117. **Daviaud N, Friedel RH and Zou H** (2018) Vascularization and engraftment of transplanted human cerebral organoids in mouse cortex. *eNeuro* **5**, ENEURO.0219.
118. **Mansour AA *et al.*** (2018) An *in vivo* model of functional and vascularized human brain organoids. *Nature Biotechnology* **36**, 432–441.
119. **Wang Z *et al.*** (2020) Cerebral organoids transplantation improves neurological motor function in rat brain injury. *CNS Neuroscience & Therapeutics* **26**, 682–697.
120. **Dong X *et al.*** (2020) Human cerebral organoids establish subcortical projections in the mouse brain after transplantation. *Molecular Psychiatry* **26**, 2964–2976.
121. **Wang SN *et al.*** (2020) Cerebral organoids repair ischemic stroke brain injury. *Translational Stroke Research* **11**, 983–1000.
122. **Ooi L *et al.*** (2020) If human brain organoids are the answer to understanding dementia, what are the questions? *Neuroscientist* **26**, 438–454.
123. **University of Cambridge** (2021) Lab-grown 'mini brains' hint at treatments for neurodegenerative diseases, University of Cambridge. Available at https://www.cam.ac.uk/research/news/lab-grown-mini-brains-hint-at-treatments-for-neurodegenerative-diseases (Accessed 27 October 2021).

https://doi.org/10.1017/erm.2022.40 Published online by Cambridge University Press